Integrated Diagnostics Holdings PLC
LSE:IDHC
Integrated Diagnostics Holdings PLC
Integrated Diagnostics Holdings Plc engages in the provision of diagnostics services including pathology and molecular diagnostics, genetics testing and basic radiology to patients and other laboratories. The firm operates in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The company is engaged in offering services in immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology and radiology. Its brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Echo-Lab (Nigeria). The company operates in approximately 507 branches. IDH offers 2,000 diagnostic pathology tests ranging from routine to advanced. Its common tests include those for cholesterol, diabetes, pregnancy, and substance abuse. Through Al Borg Scan, it offers a range of radiology services, including but not limited to magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, x-ray, mammograms, cath lab facilities, and positron emission tomography-computed tomography (PET-CT).
Integrated Diagnostics Holdings Plc engages in the provision of diagnostics services including pathology and molecular diagnostics, genetics testing and basic radiology to patients and other laboratories. The firm operates in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The company is engaged in offering services in immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology and radiology. Its brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Echo-Lab (Nigeria). The company operates in approximately 507 branches. IDH offers 2,000 diagnostic pathology tests ranging from routine to advanced. Its common tests include those for cholesterol, diabetes, pregnancy, and substance abuse. Through Al Borg Scan, it offers a range of radiology services, including but not limited to magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, x-ray, mammograms, cath lab facilities, and positron emission tomography-computed tomography (PET-CT).
Strong Revenue Growth: IDH reported first-half 2025 consolidated revenue of EGP 3.5 billion, up 42% from last year, driven by higher test volumes and price increases.
Margin Expansion: Gross profit margin rose 5 percentage points to 42%, and adjusted EBITDA margin expanded 7 points to 34%.
Profitability Surge: Adjusted net profit more than doubled year-on-year, with the margin improving to 16% from 7%.
Dividend Announced: The Board approved a $0.017 per share cash dividend for 2024, reflecting strong liquidity and financial performance.
Egypt Growth: Egypt remains the core market, with revenue up 43%, 49 new locations opened, and house call service now contributing 20% of revenues.
Operational Efficiency: Cost-to-revenue ratio dropped 9 percentage points, mainly due to raw material savings and digitalization efforts.
Saudi Expansion: Biolab KSA revenue surpassed SAR 1 million in Q2 and 1.9 million year-to-date, with new branches and aggressive marketing fueling growth.
Positive Outlook: 2025 revenue growth guidance stands at around 30%, with EBITDA margin expected to stay above 30%.
